Mitomicina Medac (Mitomycin)

Mitomycin, the active ingredient in Mitomicina Medac, is an alkylating agent presented as a sterile injectable formulation for intravenous and intravesical use. It is employed in the treatment of various solid tumours and bladder cancer in adult patients.

GNH USA supplies Mitomicina Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin is used in oncology to target rapidly dividing cancer cells across several tumour types.

Bladder cancer: intravesical administration reduces tumour recurrence after transurethral resection. Gastric cancer: systemic therapy contributes to tumour control in advanced disease. Anal canal carcinoma: systemic treatment aids in disease remission when combined with radiotherapy.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring in many patients. - Myelosuppression: reduction in white blood cells, platelets, and red cells. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Severe bone‑marrow suppression: can lead to life‑threatening infections or bleeding. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Hemolytic‑uremic syndrome: acute renal failure with hemolysis and thrombocytopenia. - Anaphylactic reaction: rapid onset of allergic symptoms requiring emergency care.

Before initiating Mitomycin therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess renal function: evaluate serum creatinine and adjust dose if impairment is present. Evaluate pulmonary status: baseline lung function tests are recommended. Avoid use in active severe infection: infection may worsen under immunosuppression. Use caution in patients with known hypersensitivity to mitomycin or related compounds. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mitomycin can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: additive bone‑marrow toxicity. - High‑dose radiation therapy: increased risk of severe tissue damage. - Strong CYP inducers (e.g., rifampin): may reduce drug exposure.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of renal impairment. - ACE inhibitors or ARBs: potential for increased nephrotoxicity. - Anticoagulants: enhanced bleeding tendency due to thrombocytopenia.